Roche releases data on cancer drug failures in Tecentriq and Taselisi
June 06, 2018 Source: Sina Pharmaceutical
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];A few days ago, Roche’s two drugs suffered setbacks. At the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago last Saturday, the cancer drugs Tecentriq and Taselisi have been shown to have limited efficacy and provide only a degree of protection against tumor progression.
In one study, the immunotherapeutic drug Tecentriq combined with other standard cancer drugs only prolonged the median disease progression time in patients with advanced squamous cell lung cancer for approximately three weeks, demonstrating the limitations of Tecentriq on lung cancer.
Advanced squamous cell carcinoma Non-small cell lung cancer accounts for about 30% of all types of lung cancer and is considered to be a particularly difficult disease to treat. A total of 1,021 patients of this type were included in the trial. One group received Tecentriq plus carboplatin chemotherapy and the new Abraxane, while the other group received only carboplatin chemotherapy and Abraxane.
Twelve months later, 25% of patients receiving Tecentriq combination therapy did not experience disease progression, while 12% of patients in the chemotherapy group did not experience disease progression. However, the median progression-free survival of Tecentriq patients was 6.3 months, compared with 5.6 months for the standard chemotherapy combination, which was only extended by 0.7 months. The researchers said that regardless of the level of tumor PD-L1 in the patient, Tecentriq combination therapy observed modest benefits. Although Roche said that the data is not yet mature, the analysis did not find Tecentriq's overall survival advantage.
At present, Roche is facing the future development pressure of Tecentriq, which hopes that the revenue of new drugs can make up for the troubles caused by the decline in the income of old generic drugs. The drug has been approved for use in previously treated patients with advanced non-small cell lung cancer and certain types of advanced bladder cancer patients, and the drug is expected to achieve sales of approximately $6 billion by 2024. Tecentriq is the third PD-1 drug to be marketed, but it is clearly at a disadvantage compared to the first two drugs, Merck Keytruda and Bristol-Myers Squibb Opdivo. Roche said that the results of the research submitted on Saturday will continue to be evaluated.
In addition, on Friday, local time, the US FDA issued a drug warning to doctors, test investigators and the public in the United States, saying that Merck Keytruda and Roche Tecentriq had dangerous signals in recent tests. Two separate studies of the two drugs at the early review of the Supervisory Board found that patients who received low-level PD-L1 inhibitor immunotherapy had a lower survival rate than those who chose normal platinum chemotherapy.
Another study, released on Saturday, showed that Roche's experimental drug, Taselisib, was only used to treat hormones for a two-month period of disease progression in women with advanced breast cancer. In addition, serious complications have occurred during the treatment of the drug. The results of the investigation led Roche to terminate the application for a new drug to the US FDA and intend to further test the drug in other types of cancer.
The trial results showed that the median time to disease progression was 7.4 months in patients receiving experimental Taselisib plus Fulvestrant hormone, compared with 5.4 months in patients receiving Fulvestrant alone. The trial involved 516 women with breast cancer who were menopausal and had a positive estrogen receptor-positive condition that had developed or recovered after prior treatment. Serious side effects of the Taselisib treatment group included diarrhea, hyperglycemia and colitis, which also led to 17% of subjects being forced to withdraw from the trial.
However, taselisib combined with conventional hormonal therapy has been successful in a phase III breast cancer trial. The results show that the drug can delay the growth of advanced breast cancer and reduce the risk of cancer progression by 30%. Taselisi is the first new drug to specifically inhibit PI3K protein (PIK3CA). In ER-positive breast cancer patients, PIK3CA gene mutations are quite common. In response to this mutation, it is also expected to bring better disease control to breast cancer patients. (Sina Pharmaceutical Compilation / Fan Dongdong)
Article, image reference source: Two Roche Cancer Drugs Get Disappointing Results
Insulator,Suspension Disc Composite Insulator,Suspension Insulators,High Voltage Suspension Insulators
Shandong Freedoms Technology Co.,Ltd , https://www.sdfreedomtech.com